Curasight (CURAS) | Spotlight

Curasight is active in the pharmaceutical industry. The company specializes in research and development of various drug candidates. The product portfolio includes, for example, research and development within Positron Emission Tomography (PET) and related ancillary services. The business is operating with the largest presence within Scandinavia. Curasight is headquartered in Copenhagen.

Quotes for Curasight A/S

Right Now

+/-: 0.07
%: 3,20%
Latest: 2.26
High: 2.26
Low: 2.09
Volume: 104 979
Turnover (DKK): 226 158
Market Value (MDKK): 101,4
Time (Latest trade): 2025-06-27 13:36

Board

CEO

Ulrich Krasilnikoff

Chairperson of the Board

Kirsten Drejer

Board

Andreas Kjær
Charlotte Vedel
Lars Trolle
Ulrich Krasilnikoff

News

2025-06-23 17:35:00 Curasight A/S announces outcome of T03 warrant exercise
2025-06-18 17:35:00 Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT[®] in brain cancer patients
2025-06-03 17:45:00 The exercise period commences for warrants of series TO3 on 4 June 2025
2025-06-02 08:15:00 Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue
2025-05-28 17:25:00 Completed registration of rights issue

News agencies

2025-06-24 07:12:29 Finwire: Curasight rapporterar marginellt utnyttjande av teckningsoptioner
2025-06-19 08:48:52 Finwire: Curasight har lämnat in ansökan till EMA om fas 1-studie
2025-06-02 08:20:17 Finwire: Curasight genomför riktad emission till garanter - utspädning på 2,1 procent
2025-05-21 08:25:31 Finwire: Curasight får in 47 miljoner danska kronor i nyemission - tecknades till cirka 47 procent
2025-05-07 08:29:32 Finwire: Curasight väljer CRO för fas 1-studie med uTREAT i hjärncancer

Analysis

2025-05-21 Redeye: Curasight: 47% subscription in the rights issue - Redeye
2025-04-29 Redeye: Curasight Q1: Securing runway to readouts - Redeye
2025-04-07 SEB Research: Curasight: Rights issue brings new investors, including partner Curium - SEB
2025-04-07 Redeye: Curasight: DKK100m rights issue announced - Redeye
2025-03-10 SEB Research: Curasight: Enticing short-term inflections, if funds secured - SEB

Videos

Largest Owners

Name	Capital %	Votes %	Date
Andreas Kjær	30,24	30,24	2023-12-31
UK Curacap ApS	19,46	19,46	2024-06-14
Carsten Haagen Nielsen	12,11	12,11	2023-12-31
Jacob Madsen	4,57	4,57	2023-12-31
Lars Trolle	2,95	2,95	2023-12-31
Chr. Olesen Holding A/S	2,01	2,01	2024-06-14
Nowo Fund Management AB	0,84	0,84	2025-05-31
Gerhard Dal	0,33	0,33	2024-06-14
Per Falholt	0,33	0,33	2023-12-31
Johan Stein	0,20	0,20	2024-06-14

Holdings by Modular Finance AB. Compiled and processed data from various sources, including VP Securities, Morningstar and The Danish Financial Supervisory Authority (Finanstilsynet)

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Curasight A/S

Quotes for Curasight A/S

Right Now

Board

News

News agencies

Analysis

Videos

Curasight - Providing answers for cancer patients

Largest Owners

Insider trading

Key Numbers

Upcoming reports

Annual reports, prospectus etc.